DNA test to help kidney transplant patients switch to a single anti-rejection drug
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial uses DNA testing and gene expression profiling to see if kidney transplant recipients can safely switch to a belatacept-only immunosuppression regimen. The goal is to simplify your anti-rejection drugs while keeping your kidney healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed a previous study called STU-2020-1339
- You must have no antibodies that might attack your donor kidney
- Your kidney function must be stable, with an eGFR over 40 mL/min for the past 3 months
- You cannot be pregnant or planning pregnancy
- You must not have significant liver problems or other major health conditions that could interfere
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a new blood test works to monitor kidney health after a transplant. It might help doctors catch problems early without needing a biopsy.
This trial is testing whether a simple blood test that looks for donor DNA can help doctors take better care of kidney transplant patients. It may help detect early signs of rejection and guide treatment decisions.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
This study tests a new blood test (called cfDNA) that may help doctors detect early signs of kidney transplant rejection before problems develop. The goal is to help keep your transplanted kidney healthy longer by catching issues early.
This trial tests a drug called BiTE to reduce high antibody levels (cPRA ≥90%) in people waiting for a kidney transplant. If it works, it might help you become eligible for a transplant sooner.
This trial uses a personalized approach (including tacrolimus medication planning and monitoring) to better understand how a kidney transplant is doing. It may help your transplant team tailor care to your kidney function over time.
Hear when a new Kidney Transplant Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.